Bicycle Therapeutics Reports Encouraging Duravelo-2 Data for Bladder Cancer Treatment
Event summary
- Bicycle Therapeutics will present initial Duravelo-2 Phase 2 trial data at the 2026 ASCO Annual Meeting, showing encouraging response rates and a potentially differentiated safety profile for zelenectide pevedotin in metastatic urothelial cancer (mUC).
- The Duravelo-2 trial evaluated zelenectide in combination with pembrolizumab, demonstrating a 62% overall response rate (ORR) and low rates of adverse events.
- Updated Duravelo-1 Phase 1 trial data showed a 59% ORR in combination with pembrolizumab and a 38% ORR as a monotherapy in mUC patients.
- The company plans to share additional Duravelo-2 data from the randomized Phase 2 trial in the second half of 2026.
The big picture
Bicycle Therapeutics' initial Duravelo-2 data positions zelenectide pevedotin as a potential alternative to current standard of care treatments for metastatic urothelial cancer, offering comparable response rates with a potentially better safety profile. The data underscores the company's focus on developing differentiated therapeutics using its proprietary bicyclic peptide technology. The upcoming presentation at the 2026 ASCO Annual Meeting will be a key milestone in validating the clinical potential of zelenectide pevedotin and attracting further investment and partnerships.
What we're watching
- Clinical Efficacy
- Whether the encouraging response rates and safety profile of zelenectide pevedotin will translate into long-term clinical benefits and regulatory approval.
- Market Differentiation
- How Bicycle Therapeutics' differentiated tolerability profile will position it against existing standard of care treatments for mUC.
- Pipeline Expansion
- The pace at which Bicycle Therapeutics can advance its pipeline of Bicycle-based conjugate molecules, including other Bicycle Drug Conjugates and Bicycle Radioconjugates.
Related topics